MIN-117

MIN-117
Clinical data
Other names	WF-516
Identifiers
	IUPAC name (2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol;
CAS Number	310392-94-0;
PubChem CID	9806065;
ChemSpider	7981825;
UNII	QM05G7NM4H;
Chemical and physical data
Formula	C25H25Cl2N3O
Molar mass	454.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O;
	InChI InChI=1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1; Key:XIYDIPLATGRHEC-SFHVURJKSA-N;

MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by for the clinical treatment of major depressive disorder (MDD).^[2]^[3]^[4] It is described as a 5-HT_1A and 5-HT_2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,^[4]^[5]^[6] and is also reported to possess affinity for the α_1A- and α_1B-adrenergic receptors.^[4]^[6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.^[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.^[7]

References[]

^ Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, et al. (2012). "Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain". PLOS ONE. 7 (8): e42589. Bibcode:2012PLoSO...742589S. doi:10.1371/journal.pone.0042589. PMC 3413639. PMID 22880045.
^ "Minerva Neuroscience". Retrieved 2015-05-19.
^ ^a ^b Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates". GlobalNewswire. Retrieved 2015-05-19.
^ ^a ^b ^c Minerva Neurosciences. "Investor Presentation March 2015" (PDF). Archived from the original (PDF) on 2015-05-20. Retrieved 2015-05-19.
^ "Company Profile for Minerva Neurosciences Inc". Reuters. Archived from the original on 2015-05-20. Retrieved 2015-05-19.
^ ^a ^b Dion D (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved 2015-05-19.
^ "Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder". BioSpace. Retrieved 2020-07-28.

External links[]

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

[KatoSaijo2012-1] Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, et al. (2012). "Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain". PLOS ONE. 7 (8): e42589. Bibcode:2012PLoSO...742589S. doi:10.1371/journal.pone.0042589. PMC 3413639. PMID 22880045.

[Minerva2015a-2] "Minerva Neuroscience". Retrieved 2015-05-19.

[Minerva2015b-3] Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates". GlobalNewswire. Retrieved 2015-05-19.

[Minerva2015c-4] Minerva Neurosciences. "Investor Presentation March 2015" (PDF). Archived from the original (PDF) on 2015-05-20. Retrieved 2015-05-19.

[Reuters2015-5] "Company Profile for Minerva Neurosciences Inc". Reuters. Archived from the original on 2015-05-20. Retrieved 2015-05-19.

[SeekingAlpha2015-6] Dion D (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved 2015-05-19.

[7] "Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder". BioSpace. Retrieved 2020-07-28.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

MIN-117

See also[]

References[]

External links[]